Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: Comparison of megadose methylprednisolone and conventional-dose prednisolone treatments

American Journal of Hematology

Volumn 80, Issue 2, 2005, Pages 113-118

  Alikasifoglu, Ayfer ^a   Yetgin, Sevgi ^a   Cetin, Mualla ^a   Tuncer, Murat ^a   Gumruk, Fatma ^a   Gurgey, Aytemiz ^a   Yordam, Nursen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; ALL; BMD; Bone mineral density; Bone turnover markers; Children; High dose methylprednisolone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ASPARAGINASE; CALCIUM; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PREDNISOLONE; PREDNOL L; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; BRAIN RADIATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; DISEASE MARKER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PREPUBERTY; PRIORITY JOURNAL; PUBERTY; REGRESSION ANALYSIS; REMISSION; SCORING SYSTEM; STEROID THERAPY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CHILD; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LUMBOSACRAL REGION; MALE; METHYLPREDNISOLONE; OSTEOPOROSIS; PREDNISOLONE; REMISSION INDUCTION; SURVIVORS;

EID: 26444527499     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20438     Document Type: Article

References (33)

1. Howard SC, Pui C. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225-243.
2. Schimiegelow M, Hertz H, Schimiegelow K, Holm K, Muller J. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children. J Pediatr Hematol Oncol 1999;21(4):268-273.
3. Katz JA, Pollock BH, Jacaruso D, Morad A. Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. J Pediatr 1993;123(4):546-522.
4. Hokken-Koelaga AC, Van Doorn JW, Hahlen K, Stijnen T, Muinck Keizer-Schrama SM, Drop SL. Long-term effects of treatment for acute lymphoblastic leukemia with and without cranial irradiation on growth and puberty: a comparative study. Pediatr Res 1993;33(6):577-582.
5. Groot-Loonen JJ, Otten BJ, Hof MA, Lippens RJ, Steolinga GB. Chemotherapy plays a major role in the inhibition of catch-up growth during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatrics 1995;96(4 Pt 1):693-695.
6. Schriock EA, Schell MJ, Charter M, Hustu O, Ochs JJ. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 1991;9(3):400-405.
7. Logghe KA, Bourguignon JP, Craen M, Benoit Y. Factors contributing to the impairment of growth in children with acute lymphoblastic leukemia. Horm Res 1988;30(2-3):62-67.
8. Moell C, Garwicz S, Marky I, Mellander L, Karlberg J. Growth in children treated for acute lymphoblastic leukemia with and without prophylactic cranial irradiation. Acta Paediatr Scand 1988;77(5):688-692.
9. Sklar C, Mertens A, Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigray of cranial irradiation. J Pediatr 1993;123(1):59-64.
10. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14(12):2205-2222.
11. Halton JM, Atkinson SA, Fraher L, et al. Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr 1995;126(4):557-564.
12. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11(11):1774-1783.
13. Van der Sluis S, Heuvel-Eibrink MM, Hahlen K, Krenning EP, de Muinck Keizer-Schrama SM. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatrics 2002;141(2):204-210.
14. Boot AM, van den Heuvel-Eibrink M, Hahlen K, Krenning E, de Muinck Keizer-Schrama S. Bone mineral density in acute lymphoblastic leukemia. Eur J Cancer 1999;35:1693-1697.
15. Crofton PM, Ahmed SF, Wade JC, et al. Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res 2000;48(4):490-496.
16. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001;15(5):728-734.
17. Yetgin S, Gurgey A, Tuncer MA, et al. A comparison of the effect of high-dose methylprednisolone with conventional-dose prednisolone in acute lymphoblastic leukemia patients with randomization. Leuk Res 1998;22:485-493.
18. Yetgin S, Tuncer MA, Cetin M, et al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17(2):328-333.
19. Crofton PM, Ahmed SF, Wade JC, et al. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998;83(9):3121-3129.
20. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999;84(9):3174-3181.
21. Arikoski P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998;20(3):234-240.
22. Tillmann V, Darlington ASE, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res 2002;17(6):1073-1080.
23. Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol 1998;16:3752-3760.
24. Nysom K, Holm K, Hertz H, Muller J, Michaelsen KF, Molgaard C. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol 2001;19(11):2970-2971.
25. Ahmed SF, Wallace WH, Crofton PM, et al. Short-term changes in lower leg length in children treated for acute lymphoblastic leukemia. J Pediatr Endocrinol Metab 1999;12:75-80.
26. Haddy TB, Mosher RB, Reaman GH. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist 2001;6:278-285.
27. Hoorweg-Nijman JJG, Kardos G, Roos JC, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol 1999;50:237-244.
28. Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muink Keizer-Schrama SMPF. Bone mineral density in children and adolescence: relation to puberty, calcium intake and physical activity. J Clin Endocrinol Metab 1997;82:57-62.
29. Gilsanz V, Carlson ME, Roe TF, Ortega JA. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr 1990;117:238-244.
30. Mushtag T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child 2002;87:93-96.
31. Weinstain RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-282.
32. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced Osteoporosis. Endocrinology 1999;140:4382-4389.
33. Strauss AJ, Su JT, Dalton VM, et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 2001;19:3066-3072.